Metraipolis › archive › dc_7abaa8da892a
Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced… — Europe PMC PMID:31914150
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/31914150
- DOI
- 10.1371/journal.pone.0227454
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-09T19:05:52.238Z
- SHA-256 of the archived text
551a6935f99f3482eee02138a0f69843c0f4681b41300fdef935b50f264bf0b8- Stable URL of this page
https://metraipolis.com/documento/dc_7abaa8da892a
How to cite
Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced… — Europe PMC PMID:31914150 — Europe PMC (en), https://europepmc.org/article/MED/31914150 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7abaa8da892a (Metraipolis archive dc_7abaa8da892a, sha256 551a6935f99f3482eee02138a0f69843c0f4681b41300fdef935b50f264bf0b8)
BibTeX
@misc{dc7abaa8da892a,
title = {Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced… — Europe PMC PMID:31914150},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/31914150},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7abaa8da892a; sha256 551a6935f99f3482eee02138a0f69843c0f4681b41300fdef935b50f264bf0b8},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/31914150. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Cholangiocarcinoma (CCA), a malignant tumor originating in the biliary tract, is well known to be associated with adverse clinical outcomes and high mortality rates due to the lack of effective therapy. Evasion of apoptosis is considered a key contributor to therapeutic success and chemotherapy resistance in CCA, highlighting the need for novel therapeutic strategies. In this study, we demonstrated that the induction of necroptosis, a novel regulated form of necrosis, could potentially serve as a novel therapeutic approach for CCA patients. The RNA sequencing data in The Cancer Genome Atlas (TCGA) database were analyzed and revealed that both receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like (MLKL), two essential mediators of necroptosis, were upregulated in CCA tissues when compared with the levels in normal bile ducts. We demonstrated in a panel of CCA cell lines that RIPK3 was differentially expressed in CCA cell lines, while MLKL was more highly expressed in CCA cell lines than in nontumor cholangiocytes. We therefore showed that treatment with both tumor necrosis factor-α (TNF-α) and Smac mimetic, an inhibitor of apoptosis protein (IAP) antagonist, induced RIPK1/RIPK3/MLKL-dependent necroptosis in CCA cells when caspases were blocked. The necroptotic induction in a panel of CCA cells was correlated with RIPK3 expression. Intriguingly, we demonstrated that Smac mimetic sensitized CCA cells to a low dose of standard chemotherapy, gemcitabine, and induced necroptosis in an RIPK1/RIPK3/MLKL-dependent manner upon caspase inhibition but not in nontumor cholangiocytes. We further demonstrated that Smac mimetic and gemcitabine synergistically induced an increase in TNF-α mRNA levels and that Smac mimetic reversed gemcitabine-induced cell cycle arrest, leading to cell killing. Collectively, our present study demonstrated that TNF-α and gemcitabine induced RIPK1/RIPK3/MLKL-dependent necroptosis upon IAP depletion and caspase inhibition; therefore, our findings have pivotal implications for designing a novel necroptosis-based therapeutic strategy for CCA patients. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-01-08). Identificativi: PMID 31914150 · PMCID PMC6948742 · DOI 10.1371/journal.pone.0227454. Pagina: https://europepmc.org/article/MED/31914150 — https://doi.org/10.1371/journal.pone.0227454. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-09T19:02:37.220Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.